# Test Results: statistics/interpretation-brainstorming.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** statistics/interpretation-brainstorming.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I have completed an experiment and am interpreting the results. I want to think through possible interpretations thoroughly, including alternatives to my initial hypothesis.

Research question: {YOUR_RESEARCH_QUESTION}

Experimental design (brief): {KEY_DESIGN_FEATURES}

Results summary:
{DESCRIBE_YOUR_KEY_FINDINGS}
- Main finding: {PRIMARY_RESULT}
- Effect size: {MAGNITUDE_IF_AVAILABLE}
- Statistical outcome: {p-values, confidence intervals, etc.}
- Secondary findings: {OTHER_NOTABLE_RESULTS}
- Unexpected findings: {ANYTHING_SURPRISING}

My initial interpretation: {WHAT_YOU_THINK_IT_MEANS}

Task: Help me think through these results critically:

1. **Support for initial interpretation**: What evidence supports my interpretation? How strong is it?

2. **Alternative interpretations**: What other explanations could produce these results? For each alternative:
   - What would it predict?
   - How could I distinguish it from my interpretation?

3. **Potential confounds**: What factors might have influenced the results that aren't captured in my interpretation?

4. **Limitations to acknowledge**: What caveats should I include when presenting these findings?

5. **Questions for follow-up**: What additional experiments or analyses would strengthen the interpretation?

6. **What the results don't show**: What conclusions would be overreach?

Constraints:
- Be genuinely critical—I want to anticipate reviewer objections
- Don't just agree with my interpretation; actively generate alternatives
- Distinguish between plausible alternatives and unlikely ones
- Focus on scientific interpretation, not just statistical significance

Context: I have completed an experiment and am interpreting the results. I want to think through possible interpretations thoroughly.

Research question: Does fecal microbiota transplantation from lean donors improve metabolic outcomes in obese mice?

Experimental design (brief):
- 3 groups (n=10 each): Control (PBS), FMT from lean donors, FMT from obese donors
- High-fat diet-induced obese mice, 8 weeks treatment
- Measured: body weight, fasting glucose, microbiome composition

Results summary:
- Main finding: FMT-lean group had significantly lower fasting glucose than Control (p=0.01) and FMT-obese (p=0.03)
- Effect size: Mean glucose 145 vs 180 mg/dL (FMT-lean vs Control)
- Body weight: No significant differences between any groups
- Microbiome: FMT-lean group showed higher diversity and different community composition
- The donor-derived taxa were detectable in recipients
- Unexpected: FMT-obese group showed slightly (non-significant) lower glucose than Control

My initial interpretation: Lean-donor microbiota transfers metabolically beneficial effects to obese recipients, potentially through specific bacterial taxa that improve glucose regulation.
```

## Model Output
```
# Critical Interpretation of FMT Metabolic Outcomes Experiment

## Preliminary Assessment

Your results are genuinely interesting, but the pattern—glucose improvement without weight change, plus the unexpected FMT-obese trend—creates interpretive complexity that deserves careful unpacking before settling on your initial hypothesis.

---

## 1. Support for Initial Interpretation

### What the evidence actually supports

**Stronger support:**
- The glucose difference (145 vs 180 mg/dL, ~19% reduction) is clinically meaningful, not just statistically significant—this is an important distinction
- p=0.01 against control is reasonably robust for n=10, though not definitive
- Donor-derived taxa detectability is critical: you have a mechanistic plausibility link, not just a correlation. Without this, the interpretation would be much weaker
- Higher diversity in FMT-lean is consistent with a large literature associating lean microbiomes with diversity

**Weaker than it appears:**
- The microbiome composition difference tells you *something changed*, but not *what change matters*. Diversity and community composition are descriptors, not mechanisms
- You have an association between lean-donor FMT and glucose improvement, but the causal chain (specific taxa → specific metabolites → glucose regulation) is entirely undemonstrated in your data
- n=10 per group means your confidence intervals are wide—the true effect could be substantially smaller or larger than observed

**Honest strength rating:** The data are *consistent with* your interpretation and provide reasonable preliminary support. They do not *establish* it. This is hypothesis-generating evidence, not hypothesis-confirming evidence.

---

## 2. Alternative Interpretations

### Alternative A: Non-specific microbiome disruption effect *(Plausible—take seriously)*

**The argument:** Any substantial microbiome perturbation in obese mice—regardless of donor metabolic status—might transiently improve glucose regulation by disrupting a dysbiotic equilibrium. The lean FMT worked better simply because it was a more "foreign" community, causing greater disruption.

**What it predicts:**
- FMT from any lean source (even non-metabolically optimized donors) would show similar effects
- The effect might be transient and reverse after treatment ends
- Antibiotic pretreatment alone might show partial glucose improvement

**How to distinguish it:**
- Include a heat-killed FMT control (same microbial material, no viable colonization)
- Extend the observation period post-treatment to test durability
- Compare FMT from lean donors with different metabolic profiles
- Critically: does the FMT-obese group's non-significant trend support this? If disruption alone matters, you'd expect *some* effect there too—and you see a hint of it

> ⚠️ **The FMT-obese trend is your most important interpretive challenge.** If disruption were the mechanism, FMT-obese should show a similar (if smaller) effect. That you see a non-significant trend rather than nothing is ambiguous—it could support disruption theory or simply be noise.

---

### Alternative B: Caloric/substrate differences in FMT material *(Plausible but probably minor)*

**The argument:** Lean-donor fecal material differs compositionally from obese-donor material in ways beyond microbiota—bile acids, short-chain fatty acids (SCFAs), undigested substrates. Recipients may be responding to transferred metabolites rather than colonizing bacteria.

**What it predicts:**
- Sterile filtrate of lean FMT would show some effect
- The effect would be rapid (days, not weeks) and not dependent on colonization success

**How to distinguish it:**
- Sterile filtrate vs. viable FMT comparison
- Measure fecal/serum SCFAs and bile acid profiles in recipients
- Timing of glucose improvement relative to confirmed colonization

**Likelihood assessment:** Probably a contributing factor rather than the sole explanation, given that donor taxa were detectable. But "detectable" ≠ "functionally colonized at sufficient abundance."

---

### Alternative C: Stress/handling confound *(Less likely but worth ruling out)*

**The argument:** FMT administration involves gavage, which causes stress. If the lean FMT group experienced different handling stress (e.g., different viscosity, volume, frequency of administration), stress-induced glucocorticoid variation could affect fasting glucose.

**What it predicts:**
- Cortisol/corticosterone differences between groups
- Glucose differences would be present even at early timepoints before colonization could establish

**How to distinguish it:**
- Corticosterone measurements (ideally already collected)
- Examine glucose trajectory over time—stress effects would appear immediately, colonization effects would build

**Likelihood assessment:** Low if your protocol was standardized, but worth one sentence of acknowledgment in your methods/limitations.

---

### Alternative D: Regression to the mean / baseline imbalance *(Must rule out)*

**The argument:** With n=10, random assignment may have produced groups with different baseline glucose levels. The FMT-lean group may have started lower and simply stayed lower.

**What it predicts:**
- Baseline glucose differences between groups before treatment

**How to distinguish it:**
- **Do you have baseline glucose measurements?** This is the single most important question for your analysis. If yes, run an ANCOVA with baseline as covariate. If no, this is a significant limitation you must acknowledge explicitly.

> 🔴 **Critical gap:** If baseline glucose wasn't measured, reviewers will raise this immediately. It's the most straightforward alternative explanation for your primary finding.

---

### Alternative E: Specific taxa vs. community-level effect *(Internal to your interpretation—important nuance)*

**The argument:** Your interpretation implies specific beneficial taxa are responsible, but your data don't distinguish between a few key taxa driving the effect versus the entire community composition shift mattering.

**Why this matters:** It affects the translational implications substantially. "Specific taxa" suggests a probiotic approach; "community-level" suggests FMT is necessary.

**How to distinguish it:**
- Correlation analysis between individual taxa abundance and glucose outcomes (you likely have the data for this already)
- Identify which donor taxa successfully colonized and at what abundance

---

## 3. Potential Confounds

| Confound | Severity | Detectable in your data? |
|----------|----------|--------------------------|
| Baseline glucose imbalance | **High** | Only if measured |
| Cage effects (coprophagy spreading microbiome between cages) | **High** | Check if cages were isolated |
| Donor variability (pooled vs. individual donors?) | **Medium** | Depends on your protocol |
| Diet consumption differences (did groups eat equally?) | **Medium** | Only if food intake measured |
| Antibiotic pretreatment differences | **Medium** | Check protocol consistency |
| Circadian timing of glucose measurement | **Low-Medium** | Standardization in protocol |
| Experimenter blinding | **Low-Medium** | Was glucose measured blinded? |

**The cage effect deserves special attention:** If mice from different groups were housed in proximity and engaged in coprophagy, microbiome cross-contamination could dilute your effect or create spurious patterns. This is a common and underappreciated confound in murine microbiome studies.

**Donor pooling question:** Were donors pooled (all lean donors combined) or were individual donors used? If individual donors, donor identity is a random effect you should account for statistically. If pooled, you've lost information about donor variability.

---

## 4. Limitations to Acknowledge

**Must acknowledge (these will be raised in review):**

1. **Mechanism is undemonstrated.** You show association between lean-donor FMT and glucose improvement; you do not show *how* this occurs. The microbiome changes are correlative with the outcome, not proven causal.

2. **No weight effect creates a puzzle.** Metabolic improvement without weight change is interesting but requires explanation. Either the effect is genuinely weight-independent (possible, and actually scientifically interesting) or the treatment duration/dose was insufficient to affect weight while still affecting glucose. You should address this directly rather than leaving it implicit.

3. **Short-term outcomes only.** Eight weeks of treatment with no post-treatment follow-up means you cannot speak to durability. Reviewers will ask whether this persists.

4. **Mouse-to-human translation is uncertain.** Murine microbiome studies have a poor track record of translating directly. The HFD model has specific limitations as an obesity model.

5. **Sample size limits precision.** n=10 provides adequate power to detect large effects but wide confidence intervals. Report CIs prominently, not just p-values.

6. **FMT-obese trend is unexplained.** You should address this in your discussion rather than ignoring it—unexplained trends that partially support alternative interpretations are exactly what reviewers notice.

**Should acknowledge but less critical:**
- Single institution, single mouse strain
- Fasting glucose alone is a limited metabolic readout (no insulin, HOMA-IR, glucose tolerance test)
- Microbiome characterization depth (16S vs. shotgun sequencing affects resolution)

---

## 5. Follow-Up Experiments

### To strengthen causal interpretation (high priority):
- **Germ-free mouse colonization** with specific taxa identified as differentially abundant—the gold standard for establishing causality
- **Antibiotic depletion + FMT** with microbiome tracking to confirm colonization is necessary for the effect
- **Glucose tolerance test (GTT) and insulin tolerance test (ITT)**—fasting glucose alone is a weak metabolic readout; these would substantially strengthen the metabolic phenotyping

### To address mechanism (medium priority):
- **Serum/fecal metabolomics** (SCFAs, bile acids, branched-chain amino acids) to identify candidate mediators
- **Intestinal gene expression** (tight junction proteins, GLP-1, inflammatory markers) to identify tissue-level responses
- **Correlation analysis** of individual taxa with glucose outcomes using your existing data—this costs nothing and should be done now

### To address durability and dose-response (medium priority):
- Extended observation post-treatment cessation
- Varying FMT frequency/dose to establish dose-response

### To address the FMT-obese puzzle (important for interpretation):
- Larger n for FMT-obese group to determine if the trend is real
- Characterize obese donor microbiome—were they truly dysbiotic, or just "less lean"?

---

## 6. What the Results Do Not Show

Be explicit about these boundaries when presenting:

❌ **"Lean-donor FMT causes weight loss in obese mice"** — Your data directly contradict this

❌ **"Specific bacterial taxa are responsible for glucose improvement"** — You have correlation with community changes, not taxon-level causation

❌ **"The microbiome is the causal mechanism"** — You've shown FMT works and microbiome changes; you haven't shown the microbiome change *causes* the metabolic change rather than both being downstream of something else

❌ **"This effect would translate to humans"** — Mouse FMT studies have limited translational track record

❌ **"FMT from obese donors has no metabolic effect"** — Your data show a non-significant trend; absence of evidence is not evidence of absence, especially at n=10

✅ **What you *can* say:** "In this murine model, FMT from lean donors was associated with significant improvement in fasting glucose compared to PBS control and obese-donor FMT, accompanied by microbiome compositional changes including increased diversity and detectable engraftment of donor taxa. These findings support further investigation of the mechanisms by which lean-donor microbiota may influence glucose regulation."

---

## Summary: Your Strongest and Weakest Points

| | Assessment |
|---|---|
| **Strongest element** | Effect size is meaningful; donor taxa detectability provides mechanistic plausibility |
| **Most important gap** | Baseline glucose data—get this analysis done immediately if data exist |
| **Most important alternative** | Non-specific disruption effect; the FMT-obese trend is your key challenge |
| **Most important follow-up** | GTT/ITT for metabolic phenotyping; germ-free colonization for causality |
| **Framing recommendation** | Present as proof-of-concept/hypothesis-generating; avoid overclaiming mechanism |

The results are genuinely interesting and publishable with appropriate framing. The glucose effect without weight change is actually a potentially novel and important finding if you lean into it rather than treating it as a puzzle to explain away—it suggests the microbiome may influence glucose homeostasis through weight-independent pathways, which is worth investigating directly.
```

## Overall Assessment
- **Recommendation:** Pass
- **Notes:**
## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
